Dear Doctor Letter (Rote-Hand-Brief) on Xagrid® (active substance: anagrelide hydrochloride): Serious cardiovascular adverse events
2013.02.06
Active substance: anagrelide hydrochloride
The pharmaceutical manufacturer is sending out information on a connection between Xagrid® and serious cardiovascular adverse events even in patients without known heart disease. This letter includes a reminder that Xagrid® is only indicated in patients at risk and only as second-line therapy.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN